
Secoisolariciresinol
CAS No. 29388-59-8
Secoisolariciresinol( —— )
Catalog No. M24214 CAS No. 29388-59-8
Secoisolariciresinol is an enterolignan precursor, it has antioxidant, and estrogen-like activities, it can significantly suppress triglyceride (TG) accumulation in 3T3-L1 adipocytes.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 288 | In Stock |
![]() ![]() |
10MG | 428 | In Stock |
![]() ![]() |
25MG | 701 | In Stock |
![]() ![]() |
50MG | 981 | In Stock |
![]() ![]() |
100MG | 1323 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameSecoisolariciresinol
-
NoteResearch use only, not for human use.
-
Brief DescriptionSecoisolariciresinol is an enterolignan precursor, it has antioxidant, and estrogen-like activities, it can significantly suppress triglyceride (TG) accumulation in 3T3-L1 adipocytes.
-
DescriptionSecoisolariciresinol is an enterolignan precursor, it has antioxidant, and estrogen-like activities, it can significantly suppress triglyceride (TG) accumulation in 3T3-L1 adipocytes.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorTNF-α
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number29388-59-8
-
Formula Weight362.4
-
Molecular FormulaC20H26O6
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCOC1=C(C=CC(=C1)C[C@@H](CO)[C@@H](CC2=CC(=C(C=C2)O)OC)CO)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.The Effect of Secoisolariciresinol on 3T3-L1 Adipocytes and the Relationship between Molecular Structure and Activity.Biosci Biotechnol Biochem. 2009 Jan;73(1):35-9.
molnova catalog



related products
-
Homovanillyl alcohol
Homovanillyl alcohol is a biological metabolite of Hydroxytyrosol.?
-
XYLOBIOSE
XYLOBIOSE ia a natural productand exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.
-
Thalidomide
Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF in vivo.